A View from the Wellcome Trust Drug-Resistant Infections Priority Programme: Creating a Sustainable Research and
Joanna Wiecek1, Gemma Buckland-Merrett1
1Drug-Resistant Infections Priority Programme, Wellcome Trust, London NW1 2BE, U.K.
Abstract:
Antibiotics have been a key component of modern medicine for decades. A critical question is why not enough antibacterials are being developed to tackle the growing challenge of drug-resistant infections. While current innovation in the early preclinical pipeline is encouraging, the journey for any new antibiotic is burdened with multiple challenges across its early and late development path. In this viewpoint, we explore the barriers to antibiotic development and how the Wellcome Trust is addressing these problems and working toward developing long-term solutions to facilitate a sustainable R&D ecosystem.
More Related Videos
10:59Using Human Induced Pluripotent Stem Cell-derived Intestinal Organoids to Study and Modify Epithelial Cell Protection Against Salmonella and Other Pathogens
Published on: May 12, 2019
08:49Cell Surface Receptor Identification Using Genome-Scale CRISPR/Cas9 Genetic Screens
Published on: June 6, 2020
Related Concept Videos
Antibiotic Selection
Development of Antibiotic Resistance
Production of Antibiotics
Microbiota Modulation by Antibiotics
Mechanism of Antibiotic Resistance in MRSA
Clinical Significance of Antibiotic Resistance
